Bicara Therapeutics (NASDAQ:BCAX) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report released on Thursday, MarketBeat reports. The brokerage issued an underweight rating and a $8.00 price target on the stock.

Several other research analysts have also recently weighed in on BCAX. HC Wainwright dropped their price target on shares of Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Wedbush reiterated an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Stifel Nicolaus set a $48.00 price target on Bicara Therapeutics in a research report on Thursday, March 27th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.43.

Bicara Therapeutics Price Performance

BCAX stock opened at $12.16 on Thursday. The business’s 50-day moving average is $12.69 and its two-hundred day moving average is $16.50. Bicara Therapeutics has a fifty-two week low of $8.91 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.08). Equities research analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new position in Bicara Therapeutics during the fourth quarter valued at $25,000. Spire Wealth Management purchased a new position in shares of Bicara Therapeutics during the fourth quarter valued at about $31,000. BNP Paribas Financial Markets bought a new stake in shares of Bicara Therapeutics in the fourth quarter worth about $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics in the fourth quarter worth about $33,000. Finally, Summit Investment Advisors Inc. bought a new position in Bicara Therapeutics during the fourth quarter valued at approximately $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.